Baupost Group activist filings are rare. But Seth Klarman just filed a 13D on Translate Bio. Here’s how Klarman’s targeted stocks have fared in the past.


Baupost Group activist filings are rare events. Seth Klarman, the renowned value investor who heads Baupost, prefers to take passive stakes in companies. Since 2006, Baupost has filed 352 passive 13G filings, and made only 25 activist 13D filings, according to data from

The returns of investors following Baupost into its activist positions have varied, with some big winners and a couple losers. Generally, holdings showing relatively high conviction by Klarman — based on the ranking of the position in the fund’s portfolio — have performed the best.

Baupost Group LLC reported a 29.2% stake in Translate Bio Inc.(TBIO) on Sept. 20. Item 4 in the 13D was boilerplate, stated:

“The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may also engage in discussions with management and the board of directors of the Issuer, other holders of Common Stock, financing sources, and other relevant parties, concerning the business, operations, governance, strategy, capitalization, ownership and future plans of the Issuer and the management and board composition of the Issuer….”

An activist investor who acquires five percent or more of a pubic company must file a 13D report with the SEC. Also, any investor, regardless of intentions, who acquires more than 20% of a company must file a 13D.

Any investor who acquires 20%+ of a public company must file a 13D with the SEC

Baupost bought 5 million shares at $10 in an underwriting of Translate shares. Over about six weeks prior to the Sept. 18 offering, Baupost bought 12,544,239 shares of TBIO on the open market at an average price of $9.36. TBIO closed at $10.02 down fractionally after the Baupost filing.

The stock represents about 1.58% of Baupost’s long portfolio after the recent purchases, making it the fund’s 19th largest holding.

Translate Bio, Inc is a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

Here are the other holdings over the years that Baupost has made 13D/activist filings on. I’ve calculated the “followers return” that investors who bought when Klarman filed the initial 13D, and sold when Baupost dropped below a 5% position, would have attained.

Facet Biotech (FACT)

Klarman first acquired Facet Biotech shares as 2008 came to a close at the height of the bear market. Baupost filed a 13G reporting a 11.60% stake. The fund filed a 13D on April 8, 2009, disclosing a 6.28% position — the fund’s 8th largest holding. The stock closed at $8.74 that day.

Abbott Laboratories (ABT) announced on March 9th, 2010 that it would acquire Facet for $27/share in cash. Klarman reported zero shares of FACT on April 21, 2010, with the stock at 27.01. Total gain from 13D filing to exit: 209% with a holding period of just over a year.

Event DateFiling DateSourceActual Reported Shares% Change in SharesPrice
2008-12-312009-01-09SC 13G2,772,092.00 8.09
2009-04-082009-04-08SC 13D4,374,407.009.76%8.74
2010-04-192010-04-21SC 13G0.00-100.00%27.01

BreitBurn Energy Partners LP (BBEPQ)

Baupost reported a 16.01% stake in Breitburn Energy on April 30, 2009, filing a passive 13G. But Klarman switched to an activist 13D stance as the shares declined, and the company announced a suspension of distributions to unit holders.

From the filing:

“the Reporting Persons determined to file this Schedule 13D to reserve their right to take steps to bring about changes to increase unitholder value which may include changes in the board composition of the Issuer’s general partner, strategy and future plans of the Issuer…”

Buying on the 13D day and selling two and a half years later would have resulted in a 226% profit, an annualized return of about 80%.

Event DateFiling DateSourceActual Reported Shares% Change in SharesUnadjusted Price
2008-09-302008-10-09SC 13G6,188,600.00 12.08
2009-04-272009-04-30SC 13D8,495,939.004.15%6.34
2011-04-302011-05-10SC 13G/A2,500,000.00-42.53%20.68


One again, an initial passive stake became an activist stake after one of Klarman’s holdings declined significantly. Baupost went activist on Idenix Pharma on Nov. 1, 2013, reporting a 5.74% stake. It was a major holding for Baupost — the fund’s #5 position.

On June 9, 2014 Merck announced it would pay $24.50 per share in cash for Idenix—a more than 230% premium to the company’s $7.34 previous close. Following Klarman into IDIX when the 13D was filed, and selling when the merger was consummated on August 12, 2014 would have generated a gain of 430% — an 825% annualized return.

Event DateFiling DateSourceActual Reported Shares% Change in SharesUnadjusted PricePrice
2011-12-312012-02-10SC 13G5,665,000.00 10.927.45
2013-11-012013-11-01SC 13D36,910,868.00123.33%4.624.95
2014-08-052014-08-12SC 13D/A0.00-100.00%24.505.50

Biotie Therapies Corp ADR (BITI)

True to form, Klarman started as a passive 5% holder of Biotie Therapies, but switched to an activist stance on January 20,2016 when Biotie received a buyout offer. In the 13D, Baupost reported it increased its stake to 17.1% of the company’s shares. It was the fund’s #25 position at the time.

Followers who bought BITI upon the 13D filing made $1.79 if they held until the merger went through. The return would have been 7.25% over less than 3 months, about 35% annualized.

Event DateFiling DateSourceActual Reported Shares% Change in SharesPrice
2015-06-302015-07-09SC 13G130,682,552.00 17.84
2016-01-192016-01-20SC 13D172,711,112.0032.16%24.67
2016-04-112016-04-13SC 13D/A0.00-100.00%26.46

Keryx Biopharmaceuticals Inc (KERX)

Keryx Bio was another biotech stock that fell significantly after Klarman bought it in May of 2014 when the stock was around $12. On Oct. 20, 2015 Baupost filed a 13D and disclosed a 34.61% stake, making KERX the fund’s #10 position. This is from the 13D:

“In connection with the acquisition of the Notes by Baupost, the Issuer agreed to use its best efforts to obtain stockholder approval for an increase in its authorized shares of Common Stock sufficient to convert the entire aggregate principal amount of Notes into shares of Common Stock and Baupost has agreed to vote in favor of any such proposal. The Issuer also agreed to increase the size of its board of directors by one and appoint a director designated by Baupost to serve until its next annual meeting of shareholders (“Annual Meeting”). For as long as Baupost continues to beneficially own at least 20% of Issuer’s Common Stock, the Issuer has agreed to nominate a director designated by Baupost for election to the Issuer’s board of directors at each Annual Meeting…”

Followers buying at $4.60 that day who held for three years until Klarman exited, would have lost 27%.

Event DateFiling DateSourceActual Reported Shares% Change in SharesPrice
2014-04-302014-05-09SC 13G9,151,600.00 12.11
2015-10-142015-10-20SC 13D42,016,276.00129.60%4.60
2018-12-112018-12-13SC 13D/A0.00-100.00%3.36

Orexigen Therapeutics Inc (OREXQ)

Orexigen was another of Baupost Group activist filings that didn’t pan out. The fund disclosed a passive 17.17% stake in that company on Oct. 9, 2015. As Oriexigen’s operations declined — it’s weight loss drug struggled to gain wide use — Klarman averaged down, even after OREXQ entered Chapter 11 bankruptcy. The position was closed at $0.01 in June of this year. Pretty much a complete loss. It should be noted that when Baupost filed its 13D, Orexigen was only a $3.9 million position, a mere 0.18% of Baupost’s $5.5 billion portfolio. So the losses from Orexigen were relatively nominal to the fund.

Event DateFiling DateSourceActual Reported Shares% Change in SharesPrice
2015-09-302015-10-09SC 13G2,582,136.30 25.30
2016-02-122016-02-12SC 13G/A2,726,839.905.60%16.40
2016-03-152016-03-24SC 13D2,726,839.900.00%5.50
2016-07-082016-07-12SC 13D/A739,796.50-72.87%4.02
2018-04-132018-04-26SC 13D/A9,996,116.001251.20%0.13
2018-10-242018-10-26SC 13D/A10,404,416.004.08%0.01
2018-10-292018-10-31SC 13D/A11,332,219.008.92%0.01
2019-05-312019-06-04SC 13D/A0.00-100.00%0.01

Viasat Inc. (VSAT)

Baupost filed a 13G on Information technology company Viasat on Nov. 9, 2009, disclosing a 14.72% position. The stock was at about $30.22. It wasn’t until Oct. 4, 2018 that Klarman filed an activist 13D on the long-held position, simultaneous with a joint press release with the company. VSAT announced it invited Baupost to participate in meetings of its Board of Directors in a non-voting observer capacity. VSAT closed that day at $62.73. The stock hit $97 in late May and recently traded at $77.68, a 23.8% gain over about 11 months, about 26% annualized.

Event DateFiling DateSourceActual Reported Shares% Change in SharesPrice
2009-10-312009-11-09SC 13G4,652,631.00 30.22
2018-10-022018-10-04SC 13D13,732,068.004.36%62.73


Do not construe anything written in this post or this blog in its entirety as a recommendation, research, or an offer to buy or sell any securities. Everything in this blog is meant for educational and informational purposes only. Do your own research before investing and don’t risk more than you can afford to lose. This article expresses my own opinions, and I am not receiving compensation for it (other than from WhaleWisdom). If you buy a book after clicking on one of the above links, I may received an affiliate fee. I do not have a business relationship with any company whose stock is mentioned in this article. I or my associates may hold positions in the stocks discussed.